Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2017, Article ID 9541370, 8 pages
Research Article

Reduced Transferrin Levels in Active Inflammatory Bowel Disease

1Department of Medical Biochemistry, Wroclaw Medical University, Chalubinskiego 10, 50-368 Wroclaw, Poland
2Department of Gastroenterology and Hepatology, Wroclaw Medical University, Borowska 213, 50-556 Wroclaw, Poland
3Ludwik Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Weigla 12, 53-114 Wroclaw, Poland

Correspondence should be addressed to Malgorzata Matusiewicz; lp.corw.demu@zciweisutam.atazroglam

Received 31 March 2017; Accepted 10 October 2017; Published 31 October 2017

Academic Editor: Toshimi Chiba

Copyright © 2017 Malgorzata Matusiewicz et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Inflammatory bowel disease (IBD) is an inflammatory disease of unclear etiopathogenesis and challenging diagnosis, frequently complicated by anemia and malnutrition. C-reactive protein (CRP) remains the only biochemical marker of clinical relevance. The aim of this study was to test hypothesis that transferrin, coinfluenced by inflammation, malnutrition, anemia, and oxidative stress, may better reflect global IBD patient’s condition than any other more specific index. Transferrin and other indices of inflammation, anemia, malnutrition, and oxidative stress were measured in 137 IBD patients (Crohn’s disease (CD): and ulcerative colitis (UC): ) and 97 controls. Transferrin is reduced in active CD and UC and negatively correlates with the disease activity scores (CD: ; UC: ). In UC, transferrin correlates negatively with CRP, erythrocyte sedimentation rate (ESR), leukocytes, platelets, interleukin-6, interleukin-10, and TNF-α and positively with albumins, cholesterol, hemoglobin, hematocrit, erythrocytes, iron, and paraoxonase-1. In CD, transferrin correlates negatively with CRP, leukocytes, platelets, interleukin-1, and interleukin-6 and positively with albumins, iron, catalase, glutathione peroxidase-1, superoxide dismutase-1, and paraoxonase-1. The associations with inflammation and anemia/malnutrition were more pronounced in UC and with oxidative stress in CD. As UC activity marker, transferrin outperforms ESR and hemoglobin, indices used in calculating the disease clinical severity score.

1. Introduction

Inflammatory bowel disease (IBD) is a debilitating, chronic, relapsing, and currently incurable inflammatory disease, the two major forms of which are Crohn’s disease (CD) and ulcerative colitis (UC). The etiopathogenesis of IBD remains unclear with the combined effect of genetic, immunological, and microbiological factors [1, 2]. Recently, the contribution of oxidative stress in the disease initiation and progression has been suggested [3, 4]. Despite intensive studies also a question of biomarkers which would aid in diagnosis, differentiation, and monitoring of the disease course and treatment mode remains open. In recent years, this problem has gained new interest, especially that there is often a poor correlation between clinical symptoms and endoscopic findings [5, 6]. Therefore, it is not surprising that every year new biomarkers are being proposed. Some of them, such as faecal calprotectin, have already found their application in IBD diagnostics and some, such as calgranulin C and B Cell-Activating Factor (BAFF), show potential as new diagnostic tool [79]. Still, a pursuit of new reliable, noninvasive, easy to perform and nonexpensive biomarkers is one of the main goals of IBD connected research [5].

Anemia is a common extraintestinal manifestation of IBD affecting up to 75% of patients [10, 11]. Its pathogenesis is multifactorial, encompassing iron deficiency anemia (IDA) and anemia of chronic disease (ACD), conditions frequently overlapping, with marginal contribution of folic acid and vitamin B12 deficiencies [12] or drug-induced anemia [11, 13, 14]. IDA in IBD results from chronic blood loss, reduced iron intake, and decreased uptake from enterocytes, while ACD is associated with inflammation and upregulated hepcidin expression, mainly by IL-6, shortened red blood cells lifespan, and hampered bone marrow response to erythropoietin [10, 11, 15]. Protein-energy malnutrition (PEM) is yet another common systemic manifestation of IBD with prevalence rates reaching those of anemia and similarly complex etiology [16, 17]. It encompasses reduced food intake, impaired digestion, and absorption, accompanied by enhanced protein loss in the course of systemic inflammation and treatment with steroids [16].

Transferrin is a glycoprotein capable of reversible iron binding, which serves as its transporter between iron donating enterocytes and macrophages and accepting erythroblasts. Systemic levels of transferrin differently respond to anemia depending on its cause, being elevated in IDA but normal/decreased in ACD. However, its utility as a differentiating marker in IBD-associated anemia is questioned since transferrin concentration varies also in response to inflammation and malnutrition [10].

The aim of our study was to evaluate transferrin levels in a large cohort of IBD patients and relate it to indices of inflammation, malnutrition, anemia, and oxidative stress. We hypothesized that a lack of specificity caused by its relation to the above-mentioned IBD-accompanying conditions might be advantageous and transferrin may better reflect the overall disease severity than any other more specific index.

2. Materials and Methods

2.1. Study Population

A cohort of 234 individuals was examined: 97 apparently healthy controls (24 volunteers recruited from hospital staff and university students and 73 blood donors from the Regional Center for Blood Donation and Therapeutics in Wroclaw, Poland) and 137 IBD patients: 63 with Crohn’s disease (36 with active and 27 with inactive disease) and 74 with ulcerative colitis (28 with active and 46 with inactive disease). IBD patients were recruited from among patients admitted to the Department of Gastroenterology and Hepatology of Wroclaw Medical University and First Department and Clinic of General, Gastroenterological and Endocrinological Surgery of Wroclaw Medical University. Patients with the coexistence of other severe systemic diseases, malignancies, or pregnancies were not included. Crohn’s disease activity was assessed using Crohn’s Disease Activity Index (CDAI) combining the evaluation of vital parameters, clinical findings, and medical history as described in detail elsewhere [18]. For the assessment of UC activity, we applied Rachmilewitz Activity Index (RI; ranging from 0 to 23), which encompasses stool frequency, number of stools with blood, general well-being, abdominal pain/cramp, fever, extraintestinal manifestations, and laboratory tests: erythrocyte sedimentation rate and hemoglobin concentration. Endoscopic findings in UC patients were evaluated as follows: a score of 0 was allocated for inactive disease, 1 for mild disease (erythema, decreased vascular pattern, and mild friability), 2 for moderate disease (marked erythema, lack of vascular pattern, friability, and erosions), and 3 for severe disease (spontaneous bleeding, ulceration). Almost all patients were treated with 5′-ASA derivatives. 19 CD and 24 UC patients were treated with corticosteroids; 18 CD and 18 UC patients were given azathioprine. Anemia was defined as a drop in hemoglobin level below 12 g/dL in female and 13 g/dL in male patients. There were 27 CD patients (7 in remission) and 24 UC patients (9 in remission) with anemia.

Characteristics of study population are depicted in Table 1.

Table 1: Characteristics of study population.

The study protocol was approved by the medical ethics committee of our university and was in accordance with the ethical standards formulated in the Helsinki Declaration of 1975. Informed consent was obtained from all of the subjects.

2.2. Analytical Methods

Blood drawn by venous puncture in a fasting state was collected into serum-separator tubes, clotted, and centrifuged (30′, 720 ×g). The obtained serum was stored at −80°C until examination. All parameters were measured in series as single day experiments to assure uniform assay conditions. Prolonged storage was avoided.

Transferrin was assessed using the enhanced immunoturbidimetric method (intra- and interassay CVs for this assay were <2%) and albumin with bromocresol blue method using appropriate kits provided by Stamar (Dabrowa Gornicza, Poland) in accordance with the supplier’s protocols. Immunoturbidimetry has been found the most accurate method of transferrin determination [19]. Interleukins-1, -6, and -10 (IL-1, -6, and -10) and tumor necrosis factor- (TNF-) α were measured by an enzyme double-antibody indirect immunoassays with PeliKine Compact human IL-1, IL-6, IL-10, and TNF-α ELISA kits, respectively, supplied by Sanquin (Amsterdam, Holland). IL-1, IL-6, and TNF-α were measured in 42 CD patients and 51 UC patients. Iron was measured colorimetrically using chromazurol B method in a presence of lipid clearing factor (LCF) using an iron assay kit provided by Emapol (Gdansk, Poland). Other laboratory indices were assessed with routine automatic procedures. Data on enzymatic antioxidants in examined cohort of IBD patients were retrieved from our earlier papers [20, 21] for a purpose of correlation analysis; in case of paraoxonase-1, the enzyme activity was measured as its arylesterase activity and data were available for 43 CD and 52 UC patients.

2.3. Statistical Analysis

Data distribution was examined using Kolmogorov-Smirnov normality test. Data on transferrin were normally distributed and hence are presented as means ± SD; the remaining data are presented either as means ± SD or as medians with IQR. Normally distributed data are analyzed using t-test for independent samples or 1-way ANOVA, while nonnormally distributed data are analyzed using Mann–Whitney test or Kruskal-Wallis test. Correlation analysis was conducted using Pearson correlation test or Spearman correlation test () depending on data distribution and character. Frequency analysis was conducted using test. Multiple regression (stepwise method) was used to coexamine transferrin and other parameters as predictors of CD and UC severity and evaluate the strength of identified associations. Receiver Operating Characteristics (ROC) curve analysis was employed to evaluate its diagnostic value. Marker overall diagnostic accuracy was expressed in terms of the area under the ROC curve (AUC) with 95% CI and for the difference between the calculated AUC and AUC = 0.5 (index with no discriminating power). Sensitivities and specificities matching a cut-off value corresponding to the highest accuracy (minimal false positives and false negatives) and Youden’s index combining sensitivity and specificity (sensitivity (expressed as a part of a whole number) + specificity − 1) were determined as well.

All calculated values were two-sided and was considered significant. The entire statistical analysis was conducted with MedCalc Statistical Software version 17.2 (MedCalc Software bvba, Ostend, Belgium;; 2017).

3. Results

We observed a significant decrease in transferrin levels in patients with active CD and UC, without differences between these two IBD forms (Figure 1). Transferrin levels negatively correlated with indices of disease clinical activity: CDAI in CD patients (Figure 2(a)) and RI in UC patients (Figure 2(b)), in whom it also correlated with endoscopic score (, ).

Figure 1: Transferrin levels in IBD patients as compared to healthy volunteers. CDa: active Crohn’s disease; CDi: inactive Crohn’s disease; UCa: active ulcerative colitis; UCi: inactive ulcerative colitis; different from controls and inactive CD and UC; different from active CD and UC; triangles represent mean values, boxes represent median values with interquartile range and whiskers represent minimum and maximum excluding outside values (open circles).
Figure 2: Correlation between transferrin levels and (a) Crohn’s Disease Activity Index (CDAI) and (b) Rachmilewitz index (RI; ulcerative colitis activity index). Regression line is depicted as a straight, solid line accompanied by 95% CI represented by dotted lines.

Transferrin in IBD patients negatively correlated with inflammatory indices, with the strongest correlations with IL-6 and hsCRP in CD and IL-6, WBC, and TNF-α in UC, although the latter association was found exclusively in patients with active disease (Table 2).

Table 2: Correlation between transferrin levels in IBD patients and inflammatory indices.

We examined transferrin association with indices of nutritional status and anemia. We found transferrin to positively correlate with all examined indices (albumin, cholesterol, hemoglobin, hematocrit, RBC, and iron) in UC patients but only with albumin and iron in CD patients (Table 3).

Table 3: Correlation between transferrin levels in IBD patients and nutritional indices.

We also examined the associations with antioxidants: serum paraoxonase-1 and erythrocyte catalase, glutathione peroxidase-1, and superoxide dismutase-1. Transferrin positively correlated with all of these parameters in CD patients but in case of UC patients exclusively with paraoxonase-1 (Table 4).

Table 4: Correlation between transferrin levels in IBD patients and antioxidants.

For comparative purposes, we examined correlation of other inflammatory indices with CDAI and RI. hsCRP, ESR, PLT, and IL-6 positively correlated with both CDAI and RI, while WBC only correlated with CDAI. No significant correlations were found for IL-1, IL-10, and TNF-α. From among antioxidants, glutathione peroxidase-1 and paraoxonase-1 correlated with CDAI and RI, while superoxide dismutase-1 correlated with CDAI. No significant correlations were found for catalase. Iron, HGB, and albumins correlated with both CDAI and RI, while cholesterol exclusively correlated with RI (Table 5).

Table 5: Correlation between IBD severity and inflammatory, nutritional, anemia, and oxidative stress indices.

To evaluate whether transferrin correlation with CDAI or RI truly reflects its association with the disease severity and is not mediated by transferrin association with inflammatory, nutritional, and anemia indices or antioxidants, we employed multiple regression. Paired transferrin and other indices were successively tested as independent variables explaining variability in CDAI or RI in CD and UC, respectively. In UC, transferrin was always retained in the regression model. It was an exclusive RI predictor when evaluated together with IL-6, CRP, albumins, cholesterol, and MCV, which explained 30% in RI variability. In other models, transferrin and ESR, PLT, HGB, paraoxonase-1, or iron were independently associated with RI. Together with platelets, transferrin explained 49% in RI variability. The results obtained in CD were similar with the exception of transferrin-albumin and transferrin-CRP models, in which albumin and CRP but not transferrin were independent predictors of CDAI and transferrin-paraoxonase-1 model, in which exclusively transferrin was independently associated with CDAI. Transferrin occurred to mediate superoxide dismutase-1 association with CDAI but not that of glutathione peroxidase-1. Transferrin alone explained 23.5% in CDAI variability and 46% together with hemoglobin or platelets.

Transferrin only tended to be decreased in anemic patients: 245 (216–274) versus 271 (259–282) mg/dL, and its diagnostic accuracy defined as the area under ROC curve was bad: AUC = 0.58 (0.49–0.67), . Although transferrin had high specificity (99% at ≤182 mg/dL), its sensitivity was low (35%) and transferrin was significantly outperformed by iron (resp., AUC = 0.83 (0.75–0.89), ; 82 and 75% at ≤11.26 μM) and HCT (resp., AUC = 0.97 (0.93–0.99), ; 99 and 84% at ≤35.8) (Figure 3(a)).

Figure 3: Transferrin performance (a) as an anemia indicator in IBD and (b) as a marker of the disease activity.

The performance of transferrin as a marker of active UC was good with AUC = 0.763 (0.650–0.854), , and sensitivity and specificity at ≤279 mg/dL were 86 and 65%. Comparably good was the performance of ESR (AUC = 0.767, 85, and 60% at >12 mm/h), PLT (AUC = 0.761, 78, and 65% at >293 × 109/L), iron (AUC = 0.743, 93, and 49% at ≤17.6 μM), HGB (AUC = 0.720, 63, and 79% at <12.2 g/dL), and paraoxonase-1 (AUC = 0.749, 75 and 78% at ≤132.5 U) (Figure 3(b)). Youden’s index for transferrin was the highest (0.51) and these of other indices were all below 0.5 (resp., 0.45, 0.43, 0.42, 0.43, and 0.42 for ESR, PLT, iron, HGB, and paraoxonase-1).

4. Discussion

Oxidative stress, inflammation, anemia, and malnutrition often coexist in active IBD, inciting each other. Inflammation triggers ACD as proinflammatory cytokines interfere with iron homeostasis and contributes to malnutrition by affecting muscle protein turnover. Undernutrition, in turn, may lead to anemia due to iron, foliate, and/or vitamin B12 deficiencies. Oxidative stress is exacerbating (if not inducing) inflammation by attracting neutrophils and macrophages into damaged tissue, which respond by releasing reactive oxygen species (ROS), deepening oxidants/antioxidants imbalance. Moreover, ROS are implicated in induction of muscle protein degradation [22], while malnutrition-associated hypoalbuminemia diminishes antioxidant capacity of serum. Nowadays, a great deal of effort is undertaken to identify specific markers that may help to detect and evaluate the severity of each of these conditions separately and thus facilitating administration of appropriate treatment. Going against the tide, however, we wondered whether a less specific marker, the levels of which vary in relation to all these conditions, may better assess global patient’s condition and could be useful in monitoring of IBD patients. Such a biomarker might meet the goals set by the Precision Medicine Initiative, which identified biomarkers studies as one of the key scientific opportunities [5]. We examined transferrin, an index coinfluenced by oxidative stress and inflammatory, nutritional, and iron status and, hence, thought to be too nonspecific to be of use in complex diseases like IBD.

Transferrin is an iron deficiency marker, superior to saturation-based indices and iron levels [23]. It also owns the potential as a differentiating tool: the levels of transferrin differently respond to IDA and ACD being elevated in the former and normal/decreased in the latter [10]. Nonetheless, transferrin measurement is recommended only in an extensive workup for anemia in IBD patients [24]. Accordingly, we found transferrin to be significantly decreased in both CD and UC, corresponding with the presentation of mixed-type anemia [10]. It positively correlated with indices of anemia, particularly iron, more pronouncedly in UC than CD. It has to be noted that Alves et al. reported that anemia was associated with clinical disease activity index only in case of UC and not CD [25]. However, as a marker of anemia, defined by a drop in hemoglobin concentration, transferrin overall performance was bad. It only tended to be decreased in anemic patients, a probable effect of opposite impact of IDA and ACD. In a subgroup of anemic patients in remission, hence without ACD interference, transferrin tended to be elevated (data not shown), consistently with observations on persisting iron and vitamin deficiencies in inactive IBD [26]. Transferrin is also considered to be a reliable measure of overall protein status. However, of the biochemical markers, albumin is recommended as PEM marker in active IBD patients [16]. Correspondingly, we found transferrin to positively correlate with albumin as well as cholesterol, a less specific index of poor nutritional status. Again, the association was more pronounced in UC. Transferrin is a negative acute phase reactant as well and as such decreases in response to inflammation. Yet, it is CRP that is universally measured to indicate ongoing inflammation and evaluate its severity. Accordingly, transferrin correlated with all measured inflammatory indices and, except for hsCRP and IL-1, these associations were stronger in UC than CD. By sequestering iron, transferrin prevents its involvement in free radical production in the Haber-Weiss reaction, constituting an important component of serum antioxidant defense. In agreement with this fact, transferrin was associated with the activities of enzymatic antioxidants: serum paraoxonase-1, erythrocyte superoxide dismutase-1, catalase, and glutathione peroxidase, yet, except for paraoxonase-1, exclusively in CD.

A decrease in transferrin concentrations occurred solely in active IBD. This might corroborate the findings that anti-TNF therapy has resulted in the improvement of iron availability and in the increase in transferrin concentrations [27, 28]. Interestingly, we found some differences between CD and UC concerning transferrin; it was generally more closely associated with oxidative stress and more loosely with inflammation (except for hsCRP and IL-1) and anemia/nutritional status in CD. Consequently, transferrin better corresponded with RI than CDAI. As hypothesized, the marker’s lack of specificity occurred to be advantageous since transferrin displayed the highest correlation coefficients with clinical assessment of disease severity in UC. As a more general severity marker, transferrin outperformed hemoglobin and ESR, parameters used in RI calculation. Transferrin alone explained almost one-third of variability in RI. Moreover, it better explained the variation in RI than hsCRP, the key inflammatory index, or IL-6, a multifunctional proinflammatory cytokine involved in ACD development [29] and muscle wasting [22]. It mediated albumin, cholesterol, and MCV association with RI as well. Together with platelets, transferrin explained half of variability in RI. We examined transferrin performance as an active UC indicator by ROC analysis and found it to display a good diagnostic accuracy, similar to that of hemoglobin, iron, ESR, platelets, and paraoxonase-1 with, however, superior combined sensitivity and specificity. The fact that transferrin was associated with RI independently from the other markers raises possibility that their coevaluation might be advantageous. However, transferrin performance needs to be reevaluated on a larger population. Since transferrin occurred to be a promising marker in UC only, the ROC analysis was restricted to UC patients (active versus inactive) what limited the number of observations and might weaken the power of analysis. Nevertheless, our results merit further studies evaluating transferrin as a prognostic factor in IBD, particularly in UC.

5. Conclusions

Reduction in transferrin levels reflects IBD activity and severity of inflammation, more tightly in UC. Transferrin is associated with anemia/malnutrition in UC while with oxidative stress in CD. As UC activity marker, transferrin outperforms ESR and hemoglobin, indices used in calculating the disease clinical severity score.

Conflicts of Interest

The authors declare that there are no conflicts of interest regarding the publication of this paper.


The study was supported by Wroclaw Medical University Grant ST739.


  1. E. F. Stange, S. P. L. Travis, S. Vermeire et al., “European evidence-based Consensus on the diagnosis and management of ulcerative colitis: definitions and diagnosis,” Journal of Crohn's and Colitis, vol. 2, no. 1, pp. 1–23, 2008. View at Publisher · View at Google Scholar · View at Scopus
  2. G. Van Assche, A. Dignass, J. Panes et al., “The second European evidence-based consensus on the diagnosis and management of Crohn's disease: definitions and diagnosis,” Journal of Crohn's and Colitis, vol. 4, no. 1, pp. 7–27, 2010. View at Publisher · View at Google Scholar · View at Scopus
  3. L. Kruidenier and H. W. Verspaget, “Review article: oxidative stress as a pathogenic factor in inflammatory bowel disease—radicals or ridiculous?” Alimentary Pharmacology & Therapeutics, vol. 16, no. 12, pp. 1997–2015, 2002. View at Publisher · View at Google Scholar · View at Scopus
  4. J. Pravda, “Radical induction theory of ulcerative colitis,” World Journal of Gastroenterology, vol. 11, no. 16, pp. 2371–2384, 2005. View at Publisher · View at Google Scholar · View at Scopus
  5. R. K. Boyapati, R. Kalla, J. Satsangi, and G.-T. Ho, “Biomarkers in Search of Precision Medicine in IBD,” American Journal of Gastroenterology, vol. 111, no. 12, pp. 1682–1690, 2016. View at Publisher · View at Google Scholar · View at Scopus
  6. J. Panes, V. Jairath, and B. G. Levesque, “Advances in Use of Endoscopy, Radiology, and Biomarkers to Monitor Inflammatory Bowel Diseases,” Gastroenterology, vol. 152, no. 2, pp. 362–373.e3, 2017. View at Publisher · View at Google Scholar · View at Scopus
  7. A. C. Manolakis, A. N. Kapsoritakis, E. K. Tiaka, and S. P. Potamianos, “Calprotectin, calgranulin C, and other members of the s100 protein family in inflammatory bowel disease,” Digestive Diseases and Sciences, vol. 56, no. 6, pp. 1601–1611, 2011. View at Publisher · View at Google Scholar · View at Scopus
  8. P. Zhang, X. Liu, A. Guo, J. Xiong, Y. Fu, and K. Zou, “B Cell-Activating Factor as a New Potential Marker in Inflammatory Bowel Disease,” Digestive Diseases and Sciences, vol. 61, no. 9, pp. 2608–2618, 2016. View at Publisher · View at Google Scholar · View at Scopus
  9. Y. Fu, L. Wang, C. Xie et al., “Comparison of non-invasive biomarkers faecal BAFF, calprotectin and FOBT in discriminating IBS from IBD and evaluation of intestinal inflammation,” Scientific Reports, vol. 7, p. 2669, 2017. View at Publisher · View at Google Scholar
  10. P. Oustamanolakis, I. E. Koutroubakis, and E. A. Kouroumalis, “Diagnosing anemia in inflammatory bowel disease: Beyond the established markers,” Journal of Crohn's and Colitis, vol. 5, no. 5, pp. 381–391, 2011. View at Publisher · View at Google Scholar · View at Scopus
  11. V. Mücke, M. M. Mücke, T. Raine, and D. Bettenworth, “Diagnosis and treatment of anemia in patients with inflammatory bowel disease,” Annals of Gastroenterology, vol. 30, no. 1, pp. 15–22, 2017. View at Publisher · View at Google Scholar · View at Scopus
  12. P. Bager, R. Befrits, O. Wikman et al., “The prevalence of anemia and iron deficiency in IBD outpatients in Scandinavia,” Scandinavian Journal of Gastroenterology, vol. 46, no. 3, pp. 304–309, 2011. View at Publisher · View at Google Scholar · View at Scopus
  13. J. P. Gisbert and F. Gomollón, “Common misconceptions in the diagnosis and management of anemia in inflammatory bowel disease,” American Journal of Gastroenterology, vol. 103, no. 5, pp. 1299–1307, 2008. View at Publisher · View at Google Scholar · View at Scopus
  14. A. U. Dignass, C. Gasche, D. Bettenworth et al., “European consensus on the diagnosis and management of iron deficiency and anaemia in inflammatory bowel diseases,” Journal of Crohn's and Colitis, vol. 9, no. 3, pp. 211–222, 2015. View at Publisher · View at Google Scholar · View at Scopus
  15. G. Weiss and L. T. Goodnough, “Anemia of chronic disease,” The New England Journal of Medicine, vol. 352, no. 10, pp. 1011–1023, 2005. View at Publisher · View at Google Scholar · View at Scopus
  16. D. D. Mijac, G. L. J. Janković, J. Jorga, and M. N. Krstić, “Nutritional status in patients with active inflammatory bowel disease: prevalence of malnutrition and methods for routine nutritional assessment,” European Journal of Internal Medicine, vol. 21, no. 4, pp. 315–319, 2010. View at Publisher · View at Google Scholar · View at Scopus
  17. L. Valentini and J.-D. Schulzke, “Mundane, yet challenging: The assessment of malnutrition in inflammatory bowel disease,” European Journal of Internal Medicine, vol. 22, no. 1, pp. 13–15, 2011. View at Publisher · View at Google Scholar · View at Scopus
  18. M. Rentsch, A. Beham, H. J. Schlitt, and K. W. Jauch, “Crohn's disease activity index and Vienna classification - Is it worthwhile to calculate before surgery?” Digestive Surgery, vol. 23, no. 4, pp. 241–249, 2006. View at Publisher · View at Google Scholar · View at Scopus
  19. R. Gottschalk, R. Wigand, C. F. Dietrich et al., “Total iron-binding capacity and serum transferrin determination under the influence of several clinical conditions,” Clinica Chimica Acta, vol. 293, no. 1-2, pp. 127–138, 2000. View at Publisher · View at Google Scholar · View at Scopus
  20. D. Boehm, M. Krzystek-Korpacka, K. Neubauer et al., “Paraoxonase-1 status in Crohn's disease and ulcerative colitis,” Inflammatory Bowel Diseases, vol. 15, no. 1, pp. 93–99, 2009. View at Publisher · View at Google Scholar · View at Scopus
  21. M. Krzystek-Korpacka, K. Neubauer, I. Berdowska, B. Zielinski, L. Paradowski, and A. Gamian, “Impaired erythrocyte antioxidant defense in active inflammatory bowel disease: impact of anemia and treatment,” Inflammatory Bowel Diseases, vol. 16, no. 9, pp. 1467–1475, 2010. View at Publisher · View at Google Scholar · View at Scopus
  22. E. Zoico and R. Roubenoff, “The role of cytokines in regulating protein metabolism and muscle function,” Nutrition Reviews, vol. 60, no. 2, pp. 39–51, 2002. View at Publisher · View at Google Scholar · View at Scopus
  23. R. C. Hawkins, “Total iron binding capacity or transferrin concentration alone outperforms iron and saturation indices in predicting iron deficiency,” Clinica Chimica Acta, vol. 380, no. 1-2, pp. 203–207, 2007. View at Publisher · View at Google Scholar · View at Scopus
  24. C. Gasche, A. Berstad, R. Befrits et al., “Guidelines on the diagnosis and management of iron deficiency and anemia in inflammatory bowel diseases,” Inflammatory Bowel Diseases, vol. 13, no. 12, pp. 1545–1553, 2007. View at Publisher · View at Google Scholar · View at Scopus
  25. R. A. Alves, S. J. Miszputen, and M. S. Figueiredo, “Anemia in inflammatory bowel disease: prevalence, differential diagnosis and association with clinical and laboratory variables,” São Paulo Medical Journal, vol. 132, no. 3, pp. 140–146, 2014. View at Publisher · View at Google Scholar · View at Scopus
  26. X. Hebuterne, J. Filippi, R. Al-Jaouni, and S. Schneider, “Nutritional consequences and nutrition therapy in Crohn's disease,” Gastroentérologie Clinique et Biologique, vol. 33, supplement 3, pp. S235–S244, 2009. View at Publisher · View at Google Scholar · View at Scopus
  27. K. Repnik, S. Koder, P. Skok, I. Ferkolj, and U. Potočnik, “Transferrin Level Before Treatment and Genetic Polymorphism in HFE Gene as Predictive Markers for Response to Adalimumab in Crohn’s Disease Patients,” Biochemical Genetics, vol. 54, no. 4, pp. 476–486, 2016. View at Publisher · View at Google Scholar · View at Scopus
  28. F. Cavallaro, L. Duca, L. F. Pisani et al., “Anti-TNF-Mediated Modulation of Prohepcidin Improves Iron Availability in Inflammatory Bowel Disease, in an IL-6-Mediated Fashion,” Canadian Journal of Gastroenterology and Hepatology, vol. 2017, Article ID 6843976, 2017. View at Publisher · View at Google Scholar · View at Scopus
  29. M. D. Fleming, “The Regulation of Hepcidin and Its Effects on Systemic and Cellular Iron Metabolism,” International Journal of Hematology, vol. 2008, no. 1, pp. 151–158, 2008. View at Publisher · View at Google Scholar